OctoPlus publishes prospectus for listing of shares issued on 18 December 2009
Click here to go to the webcast of OctoPlus' half-year results on Thursday 6 August at 10 AM CET
Click here to directly access OctoPlus' Annual Report 2008
OctoPlus has increased its fill & finish capacity by expanding its GMP facility
OctoPlus has been operating a clinical manufacturing plant in Leiden, the Netherlands since 2000. The activities of this plant are focused on small-scale clinical production.
In 2008, our facilities have been expanded with more laboratories, offices, and an additional cGMP plant. Both the existing cGMP plant and the recent expansion comprise dedicated formulation areas and areas for both production and fill and finish of parenteral dosage forms.
Our Leiden headquarters also comprise laboratories dedicated to analytical activities such as stability testing and release testing.
OctoPlus offers unique development and manufacturing expertise in the area of complex formulations, such as liposomes and microspheres, for a large range of biologicals (proteins, vaccines, antibodies, siRNA, DNA) and low-solubles (peptides, small molecules).
We collaborate with large and small biotech and pharma companies worldwide, on development of their products from pre-clinical to late-stage clinical phases.
For more information on OctoPlus' clinical manufacturing services, visit our Fill & Finish manufacturing page, or download our Clinical Manufacturing factsheet.